Varian Medical‘s (NYSE:VAR) said today that the 1st patient has been treated with its HyperArc high definition radiotherapy system at Negrar-Verona, Italy’s Sacro Cuore Don Calabria Cancer Care Center.
The Palo Alto, Calif.-based company’s HyperArc system is designed around its TrueBeam and Edge treatment platform, and delivers more compact radiation doses to fully saturate a targeted tumor while avoiding tissue outside the target zone.
“HyperArc HDRT allows us to deliver state-of-the-art radiosurgery to highly complex cases efficiently and with a very high degree of dose compactness and conformity. The 1st patient we treated with HyperArc was a complex case of multiple intracranial metastases and we were impressed with the quality and efficiency of the treatment. We now look forward to following the patient and further using HyperArc to manage the disease,” Filippo Alongi of the Sacro Cuore Don Calabria Cancer Care Center said in a prepared statement.
Varian Medical said that while its HyperArc system is cleared in the US, the Varian Eclipse treatment planning software is currently FDA 510(k) clearance pending.
“We are very excited about this 1st treatment using HyperArc as we usher in a new era of precision in radiotherapy and radiosurgery for cancer patients,” Varian oncology systems biz prez Kolleen Kennedy said in a press release.
Last month, Varian Medical said it won FDA 510(k) clearance for its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system.
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.